Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
AIN
ModerateOpen →
PD-L1 immune checkpoint inhibitor
Sugemalimab
Cejemly · PD-L1 inhibitor
A full-length anti-PD-L1 antibody whose kidney is its immune system: rare but real autoimmune interstitial nephritis.
Moderate2021 (China NMPA); EU (Cejemly) 2025 · approved 2021
First-line metastatic squamous and non-squamous NSCLC (with platinum-based chemotherapy)Consolidation therapy for stage III unresectable NSCLC not progressing after concurrent or sequential chemoradiotherapy
Signature kidney injury
Acute Interstitial Nephritis
No sugemalimab-specific renal-injury incidence has been published; the GEMSTONE registrational trials reported no nephritis among the most common grade 3-4 treatment-related adverse events (which were dominated by myelosuppression and immune-mediated pneumonitis). By extrapolation from the PD-1/PD-L1 checkpoint-inhibitor class, immune-related AKI occurs in roughly 2-5% of treated patients (higher with combination checkpoint blockade), with clinically significant/biopsy-confirmed acute interstitial nephritis being the dominant lesion.
Source: Class incidence and lesion distribution from Cortazar et al., J Am Soc Nephrol 2020 (PMID 31896554) and the ASON position statement, Kidney Int 2024 (PMID 39455026); sugemalimab trial safety from GEMSTONE-302 (PMID 35038432) and GEMSTONE-301 (PMID 35038429), in which renal events were not among the prominent toxicities.
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityPartially reversible
Evidence0 refs
Nephron map
Glomerulus
Proximal Tubule
Distal Tubule / Collecting Duct
InterstitiumSupporting tissue around the tubules
Acute Interstitial Nephritis
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Mechanism of kidney injury
Mechanism is immune-mediated, not directly cytotoxic. PD-L1 blockade lifts peripheral tolerance and permits activation of autoreactive T cells within the renal interstitium, producing a T-cell-rich acute (tubulo)interstitial nephritis — the same off-target autoimmune process responsible for checkpoint-inhibitor colitis, hepatitis, and pneumonitis. Loss of PD-L1-mediated protection of tubular epithelium, reactivation of memory T cells primed by concomitant drugs (notably proton-pump inhibitors and NSAIDs), and a possible drug-hapten effect have all been implicated. Less commonly, immune dysregulation produces glomerular lesions (minimal change, pauci-immune/ANCA-associated GN) or electrolyte disturbances; frank ATN is usually a comorbid/ischemic rather than a direct effect.
Clinical presentation
Typically an asymptomatic, subacute rise in serum creatinine detected on routine labs, often weeks to months into therapy. Sterile pyuria and subnephrotic proteinuria are common; eosinophiluria and peripheral eosinophilia are inconstant and insensitive. Many patients have concurrent extrarenal immune-related adverse events (rash, colitis, thyroiditis, pneumonitis) that raise suspicion. Overt nephritic or nephrotic presentations are uncommon. Fever and the classic AIN triad are frequently absent.
Anticancer mechanism
Sugemalimab is a fully human IgG4 monoclonal antibody that binds programmed death-ligand 1 (PD-L1) on tumor cells and antigen-presenting cells, blocking its engagement of PD-1 (and CD80) on T cells. This releases the inhibitory brake on tumor-reactive cytotoxic T lymphocytes, restoring antitumor immunity. It was developed and validated in the GEMSTONE-301 (stage III unresectable NSCLC consolidation) and GEMSTONE-302 (first-line metastatic NSCLC) phase 3 trials.
Management
Per ASON consensus and checkpoint-inhibitor irAE guidelines: grade the AKI, hold sugemalimab, and exclude alternative causes (prerenal, obstructive, ATN, other nephrotoxins). For presumed immune-mediated AIN, discontinue offending co-medications (PPIs, NSAIDs) and start corticosteroids (e.g., prednisone ~0.5-1 mg/kg/day, higher for severe/stage 3 disease) with a taper over 4-6+ weeks guided by creatinine recovery. Kidney biopsy is recommended when feasible to confirm AIN and exclude glomerular/ATN lesions, especially before committing to prolonged steroids or rechallenge. Steroid-refractory cases may need additional immunosuppression (e.g., mycophenolate). Rechallenge is individualized — recurrent AKI occurred in roughly a quarter of rechallenged patients in the multicenter cohort.Lesion-level management framework
Risk factors
- Lower baseline eGFR (pre-existing CKD)
- Concomitant proton-pump inhibitor use
- Combination checkpoint-inhibitor therapy
- Concurrent NSAIDs or other AIN-associated drugs
- Concurrent extrarenal immune-related adverse events
- Prior immune-related adverse event on checkpoint therapy
Prevention
- Check baseline and serial serum creatinine and urinalysis before and during each cycle
- Review and discontinue unnecessary AIN-associated drugs (PPIs, NSAIDs) before/during therapy
- Early nephrology referral and low threshold for kidney biopsy when AKI develops without an obvious alternative cause
- Exclude and treat competing causes (volume depletion, contrast, obstruction, other nephrotoxins) before attributing AKI to the drug
Note · Sugemalimab (CS1001/Cejemly) is a fully human IgG4 anti-PD-L1 antibody approved by China's NMPA in 2021 and authorized in the EU (Cejemly) in 2025 for NSCLC. Renal-specific data are sparse; this profile reasons primarily from checkpoint-inhibitor class evidence and is educational, not medical advice.
Clinical depth
Renal dose adjustment
No pharmacokinetic dose adjustment is required for renal impairment — as a ~150 kDa monoclonal IgG antibody, sugemalimab is cleared by reticuloendothelial proteolysis, not renal excretion, and is dosed as a fixed/flat IV dose (1200 mg every 3 weeks; 500 mg maintenance with pemetrexed in non-squamous disease). Management of nephrotoxicity is by holding or permanently discontinuing the drug per irAE grade, not by dose reduction.
Dialyzability & ESKD dosing
Not dialyzable. Large therapeutic IgG monoclonal antibodies are not removed by hemodialysis or peritoneal dialysis; no supplemental dosing is needed for patients on renal replacement therapy.
Differential diagnosis
Distinguish immune-mediated AIN from: prerenal azotemia (volume depletion, sepsis), ATN (ischemic, contrast, cisplatin co-therapy), obstruction, and tumor-related causes (hypercalcemia, infiltration). Concomitant platinum chemotherapy in the GEMSTONE regimens can independently cause ATN and Mg/electrolyte wasting, confounding attribution. Subnephrotic proteinuria with bland-to-pyuric sediment and a delayed onset favor AIN; abrupt onset after a hypotensive/ischemic insult favors ATN. Biopsy is the discriminating test when the clinical picture is ambiguous.
Monitoring
- Serum creatinine/eGFR at baseline and before each cycle
- Urinalysis with microscopy (pyuria, proteinuria, casts)
- Spot urine protein-to-creatinine ratio if proteinuria emerges
- Serum electrolytes including magnesium, potassium, sodium
- Assessment for concurrent extrarenal immune-related adverse events
Key trials & series
- GEMSTONE-302 (NCT03789604): first-line sugemalimab + platinum chemotherapy vs placebo + chemotherapy in metastatic squamous/non-squamous NSCLC — PFS HR 0.48; renal events not among prominent toxicities (PMID 35038432)
- GEMSTONE-301 (NCT03728556): sugemalimab vs placebo consolidation after chemoradiotherapy in stage III unresectable NSCLC — PFS HR 0.64; grade 3-4 irAE dominated by pneumonitis (PMID 35038429)
Clinical pearls
- Sugemalimab's kidney signature is the checkpoint-class lesion: immune-mediated acute interstitial nephritis, not direct tubular toxicity.
- Renal AKI was not a prominent toxicity in the GEMSTONE registrational trials — the headline immune toxicity was pneumonitis — so sugemalimab-specific renal incidence is unquantified and must be inferred from the PD-1/PD-L1 class.
- Onset is characteristically delayed (median ~14 weeks), so a creatinine rise months into therapy should still trigger an irAE workup.
- PPIs and NSAIDs are the most actionable risk amplifiers — stop them before reaching for steroids.
- Because it is a fixed-dose IgG antibody cleared by proteolysis, no renal dose adjustment is needed and it is non-dialyzable; the only renal 'dose adjustment' is holding/stopping the drug.
- In GEMSTONE regimens the co-administered platinum can independently cause ATN and Mg wasting — don't reflexively attribute every creatinine bump to the checkpoint inhibitor.
Beyond the kidney
Class-level context for the major non-renal toxicities of pd-l1 immune checkpoint inhibitors.
Endocrine
Thyroiditis, hypophysitis, diabetes
- Thyroiditis, hypophysitis, type-1 diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Immune colitis
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Immune hepatitis
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Pneumonitis
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Rash, vitiligo, rarely SJS/TEN
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkSugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.Zhou C et al. · The Lancet Oncology 2022 · PMID 35038432Pivotal first-line metastatic NSCLC registrational trial; source for safety profile showing renal events were not among prominent toxicities (myelosuppression and immune-mediated pneumonitis dominated).PMIDSugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.Zhou Q et al. · The Lancet Oncology 2022 · PMID 35038429Registrational stage III consolidation trial; corroborates that immune-mediated pneumonitis, not nephritis, was the leading severe immune toxicity.LandmarkClinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.Cortazar FB et al. · Journal of the American Society of Nephrology 2020 · PMID 31896554Landmark multicenter cohort defining the checkpoint-inhibitor renal signature: AIN dominant on biopsy (93%), median onset ~14 weeks, PPI/CKD/combination therapy as risk factors, and recovery/rechallenge outcomes — the class basis for this PD-L1 agent.PMIDDiagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology.Herrmann SM et al. · Kidney International 2024 · PMID 39455026Current consensus on incidence, mechanism, diagnosis (including biopsy), corticosteroid management, and rechallenge for checkpoint-inhibitor AKI; basis for management and prevention guidance.